The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Standardizing radiologic reporting of response to improve the patient experience: Comparing response categories of RECIST 1.1 and a novel, real-world, standardized, oncologic response lexicon derived from clinical radiology reports.
 
Monica F Chen
Stock and Other Ownership Interests - docs; FIGS; Nordisk; Quest Diagnostics
Research Funding - ASCO; NIH
Travel, Accommodations, Expenses - AACR; ASCO
 
Weining Ma
No Relationships to Disclose
 
Betty Ann Caravella
No Relationships to Disclose
 
Guilherme Harada
Speakers' Bureau - AstraZeneca; Lilly; Merck; MSD; Pfizer
 
Natalie Gangai
No Relationships to Disclose
 
Grace Grimaldi
No Relationships to Disclose
 
Alexandra Waksmundzki
No Relationships to Disclose
 
William Trevenen
No Relationships to Disclose
 
Kaelyn Kohlasch
No Relationships to Disclose
 
Margaret Reynolds
No Relationships to Disclose
 
Victoria Martorana
No Relationships to Disclose
 
Alexander E. Drilon
Stock and Other Ownership Interests - mBrace; Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EcoR1 Capital; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Osimertinib Selpercatinib; Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Richard K. G. Do
Honoraria - ALK (I); Genentech (I)
Consulting or Advisory Role - Ascelia; Ascelia; DBV Technologies (I)
Patents, Royalties, Other Intellectual Property - Elsevier, surgery textbook; UptoDate chapters on Food Allergy (I)